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Abstract
Stroke is a major cause of disability and leading cause of death in the northern hemisphere. Only recently it became evident
that cerebral ischemia not only leads to brain tissue damage and subsequent local inflammation but also to a dramatic loss
of peripheral blood T-cells with subsequent infections. However, only scarce information is available on the activation status
of surviving T cells. This study therefore addressed the functional consequences of immunological changes induced by
stroke in humans. For this purpose peripheral blood T-cells were isolated from 93 stroke patients and the expression of
activation makers was determined. In addition ex vivo stimulation assays were applied to asses the functionality of T cells
derived from blood of stroke patients. Compared to healthy controls, stroke patients demonstrated an enhanced surface
expression of HLA-DR (p,0.0001) and CD25 (p=0.02) on T cells, revealing that stroke leads to T cell activation, while CTLA-4
remained undetectable. In vitro studies revealed that catecholamines inhibit CTLA-4 upregulation in activated T cells. Ex
vivo, T cells of stroke patients proliferated unimpaired and released increased amounts of the proinflammatory cytokine
TNF-a (p,0.01) and IL-6 (p,0.05). Also, in sera of stroke patients HMGB1 concentrations were increased (p=0.0002). The
data demonstrate that surviving T cells in stroke patients remain fully functional and are primed towards a TH1 response, in
addition we provide evidence that catecholamine mediated inhibition of CTLA-4 expression and serum HMGB1 release are
possible mediators in stroke induced activation of T cells.
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Introduction
Stroke is a major cause of disability and leading cause of
death in the northern hemisphere, second only to cardiac
disease, and is accompanied by a grave economic impact [1].
T h ec l i n i c a lc o u r s eo fs t r o k ep a t i e n t si sn o ts o l e l yd e t e r m i n e db y
the extent of brain damage and the resulting neurological
deficit, but often complicated by post stroke infections. These
affect between 10% and 35% of patients in the week following
stroke [2,3]. Only recently it became evident that cerebral
ischemia not only leads to brain tissue damage and subsequent
local inflammation but also to dramatic alterations of the
peripheral immune system. First reported in a mouse model of
stroke [4], we and others have demonstrated that also in
humans stroke induces an immediate loss of lymphocytes. The
rapid lymphocytopenia, predominantly seen among CD4
+ T-
cells, is attributed to apoptosis due to increased cortisol and
catecholamine release. A delayed recovery of the CD4
+ T-cell
counts indicates an increased risk for subsequent infection. In
addition to cellular parameters, serum cytokine concentrations
have also been shown to differ between patients with and
without subsequent infections. Of interest, IL-10 a cytokine with
strong anti-inflammatory properties and IL-6 known for its
proinflammatory capacities are both elevated in stroke patients
with subsequent infection [5,6,7].
To better understand the role of soluble modulators in stroke
induced immunosuppression we studied prototypical pro- and
anti-inflammatory cytokines and determined HMGB1 levels.
HMGB1 is released into serum either by secretion from activated
monocytes, T cells, thrombocytes or endothelial cells or by passive
release from necrotic tissue [8,9,10]. Serum HMGB1 strongly
promotes inflammation, regulates dendritic cell function and
migration, skews the T cell response towards a Th1 profile and
induces proliferation and the release of IL-6 [11,12,13] Conse-
quently, HMGB1, which has been shown to be elevated within
24 hours following stroke or myocardial infarction, could act as
important player in the modulation of post stroke immune
responses. Furthermore, this molecule has been shown to
contribute to brain tissue destruction following brain injury
[13,14,15]. However, to determine the biological relevance of
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8718elevated serum HMGB1 the concentrations of its functional
inhibitors the soluble and the endogenous secretory receptor for
advanced glycation end products (sRage and esRage) need to be
determined [16].
The more recent research on immunological sequelae of
ischemic stroke has delineated mechanisms that result in rapid
alterations of the immune system and identified several immuno-
logical factors associated with subsequent infection. Why these
Table 1
Total No.
Age Mean
(Range)
NIHSS Median
(Range)
Lesion Volume (mm
3)
Median (Range) Male Female
Nonstroke control subjects
1) 17 65 NA NA 6 8
(50–94)
Total patients included 93 69.8 15 141120 47 46
(41–92) (2–26) (441–2 954 304)
Infected cohort
2)3) 17 70.6 17 162180 10 7
(49–92) (2–26) (10230–2 954 304)
Noninfected cohort
3) 24 63.2 9 64638 14 10
(43–88) (2–20) (441–2 551 298)
Infection status not set
3) 52 72.5 17 131585 23 29
(41–89) (3–26) (689–617792)
1)Nonstroke control subjects were healthy individuals (n=12) or had other diseases (Parkinson’s disease n=1, Bell’s palsy n=1, hypertensive crisis n=1, diabetes
mellitus n=1,or polyneuropathy n=1).
2)Infected cohort patients suffered from: 14 pneumonia n=14, ,fever of unknown origin n=1, erysipelas n=1, intravenous catheter abscess n=1. 3 patients additionally
aquired urinary tract infection.
3)Patients were assigned as described in material and methods section.
NA: not applicable.
doi:10.1371/journal.pone.0008718.t001
Figure 1. Th1-type cytokines are downregulated in stroke patients. IL-2,IL-12p70, IFN-c and TNF-a serum cytokine levels are significantly reduced
in sera of stroke patients (grey bars) compared to healthy controls (white bars) in the first two weeks following stroke. * p,0.05; ** p,0.01; *** p,0.001.
Boxes with medians and whiskers min to max. n(IL-2, IL-12p70, TNF-a)=16; 20; 20; 21; 13; n(IFN-c)=16; 20; 20; 19; 12 (control; day 0; day 1; day 7; day14).
doi:10.1371/journal.pone.0008718.g001
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is largely unexplored. This study therefore addressed the
functional consequences of immunological changes induced by
stroke in humans. Of special interest were the kinetics of serum
cytokine concentrations and differences in T cell function between
stroke patients with subsequent infection and those, who remained
free from this complication.
Materials and Methods
Patients with onset of stroke symptoms less than 12 hours before
admission to the stroke unit and without clinical signs of infection
on admission were eligible for recruitment into the study. Ischemic
stroke was diagnosed clinically and by cerebral CT. Routine
cerebral CT images were acquired on a 16-row multislice CT
scanner (Somatom 16; SIEMENS Medical Systems). To calculate
lesion size, images were analyzed using OSIRIX 2.5.1.
Blood was obtained immediately on admission and between
6:00 a.m. and 7:00 a.m. on days 1, 7 and 14 thereafter. A previous
publication included data from 46 of the 93 patients and 14 of the
17 controls analysed in the current study [7]. Patient details are
summarized in Table 1.
Ethics Statement
The study protocol was approved by the ethics committee of the
Medical Faculty, University of Greifswald (No. III UV 30/01). All
patients gave fully written informed consent directly or through a
surrogate where appropriate.
Definition of Infection
For the purpose of this study, we applied the following criteria to
defineinfection:(1)presenceofclinicalsignsofinfection(pneumonia,
urinary tract infections, fever of unknown origin); (2) serum
concentrations of C- reactive protein .50 mg/mL; and (3)
procalcitonin serum concentrations .0.5 ng/mL. To compare
patients who developed infection after stroke with those who did
not, 2 cohorts were formed. In the infected cohort, all 3 criteria for
infectionhad tobefulfilledonday7or14.Inthe noninfectedcohort,
none of the criteria was matched throughout the whole study period.
Patients who matched some criteria but not all were not assigned to
either cohort. Patients with signs of infection on admission were not
recruited into the study as published previously [7].
Peripheral blood mononuclear cells (PBMC) were isolated by
standard ficoll gradient centrifugation. Cell culture was performed at
a cell density of 2610
5 cells/well in 96 well u-bottom plates (Nunc,
Roskilde, Denmark) in 200 ml RPMI supplemented with 1%
glutamine, 1% penicillin, 1% streptomycin and 10% human AB
serum. For the cytokine and proliferation assays cells were incubated
with 1 mg/ml PHA (Abbot, Wiesbaden, Germany) for 72 h. Cell
culture supernatants were collected after 48 h of incubation.
IFN-c, IL-1b, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-a
and TNF-b were measured using a Human Th1/Th2 multiplex
kit (Bender MedSystems, Vienna, Austria). The cytokines were
quantified by FACS analysis on a Becton Dickinson FACScan.
Data were evaluated using the FlowCytomix Pro 2.1 software
package provided by Bender MedSystems. IL-17 was detected by
ELISA (eBioscience, Frankfurt, Germany) following the manufac-
turer’s protocol as was HMGB1 (IBL, Hamburg, Germany).
Cortisol and metanephrine yield was determined in serum
samples after storage at 280uC by ELISA according to the
manufacturer’s recommendations (Cortisol or MetCombi plasma
ELISAH; IBL, Hamburg, Germany).
CTLA-4 expression was determined on peripheral blood T cells
from human stroke patients and healthy age-matched controls by
Figure 2. HMGB1 is upregulated in serum of stroke patients.
HMGB1 is upregulated in serum of stroke patients (grey bars) compared
to healthy controls (white bars) in the first two weeks following stroke
while its decoy receptors sRAGE and esRAGE remain indistinguishable
within 48h following stroke. ** p,0.01; *** p,0.001. Medians and
interquartile ranges. n(HMGB1)=16; 87; 84; 46; 24; n(sRAGE,) 12; 32;
29, esRAGE)=10; 37; 34, (control; day 0; day 1; day 7; day14).
doi:10.1371/journal.pone.0008718.g002
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acetone-fixed, and Fcc-receptors were blocked with human IgG
(Cohn fraction II, Sigma, Deisenhofen, Germany). Slides were
incubated with anti-human CD3 and biotinylated anti-human
CTLA-4 monoclonal antibodies (BD Biosciences, USA) and then
post-fixed with 4% PFA (Sigma, Deisenhofen, Germany).
Endogenous peroxydase was inactivated with 3% H2O2 (Merck,
Darmstadt, Germany). After incubation with Streptavidine-POD
(1:500 in PBS) and biotinyltyramid (1:200 in amplification diluent)
for signal amplification (TSA
TM Biotin System, NEN Life Science
Products, Boston, MA, USA), the cytospins were finally incubated
with goat anti–mouse IgG1-FITC (Southern Biotechnology
Associates,Birmingham, AL, USA) and streptavidine-TRITC for
visualization (Jackson Immuno Research, Dianova, West Grove,
PA, USA). Microscopic quantification was performed by observ-
ers, who were blinded for the identity and grouping of the patient.
A minimum of 500 cells were evaluated per sample.
Hormone effects on PHA stimulated PBMC were assessed in
48 h cultures in the presence of 1610
27 M epinephrine or
norepinephrine or 1610
26 M dexamethasone (all Sigma, Dei-
senhofen, Germany) and the appropriate control conditions.
Proliferation was measured by standard
3H-thymidin incorpora-
tion assays.
3H-thymidin (Amersham, Braunschweig, Germany) was
added to the cell culture after 48 h. Its incorporation was determined
on a phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA)
after additional incubation of 18 h. Proliferation is shown as
stimulation index (SI) calculated as counts per minute (CPM) with
stimulants/CPM without stimulants. Cytokine concentrations of
supernatants are given as the differences between PHA-stimulated
and unstimulated values.
FACS Analysis of Helper Cell Activation
Lymphocyte subpopulations were estimated on a FACSCalibur
(Becton Dickinson, Heidelberg, Germany). Aliquots of 100 mlo f
whole blood, anticoagulated with EDTA, were incubated with
appropriate combinations of fluorescence-conjugated monoclonal
antibodies. After lysing of erythrocytes (FACS Lysing solution,
BD Biosciences, Heidelberg, Germany) cells were washed once
(PBS, 1% FCS, 0.2% NaN3) before measurement. Monoclonal
antibodies used to determine expression of cell surface molecules
were CD25-FITC (DAKO Cytomation, Hamburg, Germany),
CD4-PerCP or CD4-PE, CD3-PerCP, and HLA-DR-FITC (all
BD Biosciences, Heidelberg, Germany). Absolute number of
lymphocytes used for calculation of absolute counts of lympho-
cyte subpopulations were estimated in a separate Trucount tube
stained with anti-CD45-PerCP mAb (BD Biosciences, Heidel-
berg, Germany) measured without washing after lyses of
erythrocytes.
Statistical Analysis
All data sets were tested for deviations from Gaussian
distribution using the Kolmogorov-Smirnov test. Data that passed
the test were analyzed using repeated-measures ANOVA and
Bonferroni’s multiple comparison test as post test. Data failing the
normality test were analyzed using the Friedmann test with
Dunn’s multiple comparison test as post test. The comparison of
two sets of data was performed using paired or unpaired student’s
t-test, as appropriate for normally distributed data and Kruskal
Wallis test for those without Gaussian distribution. All analyses
were carried out using the software GraphPad-PRISM 5.0
Figure 3. CD4
+ T-cells in the peripheral blood of stroke patients are activated. Comparison of expression of activation markers on
lymphocytes between healthy controls (white bars) and stroke patients (grey bars) in the first two weeks following stroke reveal that CD4
+ T-cells in
the peripheral blood are activated. * p,0.05; ** p,0.01; *** p,0.001. Medians and interquartile ranges. n(CD4
+
CD25
+
, CD25
+
%CD4
+
)=14; 33; 32; 24; 14;
n(CD4
+
HLA-DR
+
)=12; 64; 66; 42; 22; n(HLA-DR
+
%CD4
+
)=12; 63; 66; 43; 22; (control; day 0; day 1; day 7; day14).
doi:10.1371/journal.pone.0008718.g003
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regarded as significant.
Results
Th1-Type Cytokines Are Downregulated in Sera of
Patients with Acute Stroke
To characterize the effects of ischemic stroke on the cytokine
milieu in the serum pro- and anti-inflammatory cytokines in stroke
patients and control subjects were determined. Serum concentra-
tions of the proinflammatory cytokines TNF-a (p=0.0001), IL-
12p70 (p,0.0001), IL-2 (p=0.0016) and IFN-c (p,0.05) were
significantly decreased (Fig. 1). IL-4 and IL-8 serum concentra-
tions were not altered, while IL-1b, IL-5, and TNF-b remained
below the threshold of detection in the majority of patients and
controls (data not shown).
Serum HMGB1 Is Upregulated in Stroke Patients
HMGB1 was rapidly upregulated following stroke and elevated
serum levels persisted throughout the study period of 14 days
(p=0.0002). Importantly, the serum concentrations of the natural
inhibitors of HMGB1, sRAGE and esRAGE, did not change (Fig. 2).
Since HMGB1 has been shown to induce IL-6 we tested
relations between infarction size, IL-6 and HMGB1. While
HMGB1 serum levels significantly correlated with IL-6 (on day
7: r=0.4896, p=0.0152), this was not the case for brain tissue
destruction as assessed by CT morphometry (data not shown).
CD4
+ T-Cells in the Peripheral Blood of Stroke Patients
Are Activated
It is well documented that following stroke a large fraction of T
cells is rapidly lost from the peripheral blood. To determine the
activation status of the remaining T cells the expression of the
established T cell activation markers IL-2 receptor (CD25) and
HLA-DR were measured. Compared to controls, an increased
proportion of CD4
+ T-cells expressed CD25 (p=0.02) or HLA-
DR (p,0.0001), respectively (Fig. 3). This corresponded to a net
increase in CD4
+ HLA-DR
+ T-cell numbers (p=0.0055) despite
the reduction of the total numbers of CD4
+ T-cells. A similar trend
was observed for CD4
+CD25
+ T-cells. This shows that in stroke
CD4
+ T-cells in the peripheral blood become activated.
CTLA-4, which is constitutively expressed on Treg cells but is
also up-regulated by activation of T effector cells, was determined
by immunoflourescence staining. Interestingly no CTLA-4
upregulation was observed (Fig. 4A).
Catecholamines Inhibit CTLA-4 Expression on Activated
T-Cells
We hypothesized that stroke-induced catecholamines and
steroids could account for the lack of CTLA-4 upregulation and
examined the influence of these hormones on CTLA-4 expression
in vitro (Fig. 4B). Stimulation with the mitogen PHA induced strong
upregulation of CTLA-4 on CD4
+ T-cells, which was counteract-
ed by the addition of catecholamines (p,0.0001; Fig. 4) but not by
dexamethasone into the cell culture (data not shown).The
concentrations of dexamethasone, epinephrine and norepineph-
rine used in these experiments did not enhance apoptosis, which
excludes cell death as a reason for the catecholamine-mediated
changes in CTLA-4 expression (data not shown). The data suggest
that the high concentrations of catecholamines in acute stroke
patients could explain why CTLA-4 was not upregulated on
activated CD4
+ T-cells.
Surviving T Lymphocytes Are Functional
To assess whether the surviving lymphocytes in stroke patients
retained their functional capacity, ex vivo stimulation assays were
performed. The proliferative capacity of the PBMC was unaltered
during the first week following ischemic stroke (Fig. 5 A). The cells
were stimulated with PHA and cytokine release was measured.
This revealed a predominance of the proinflammatory cytokines
IL-6, IL-1ß, TNF-a and TNF-b (Fig. 5 B–E) while IL-17, HMGB1
and IL-4, IL-5, IL-8, IL-10, IL-12p70 and IFN-c remained
unchanged (data not shown). Thus, the function of the surviving
lymphocytes was intact and skewed towards proinflammation.
Differences between Stroke Patients with and without
Subsequent Infection
We have previously reported that a delayed recovery of CD4
+
T-cell counts predisposes to a subsequent infection. In agreement
with this finding absolute numbers of CD4
+CD25
+ T-cell were
higher in the non-infected cohort (p,0.05;). while the the relative
proportion of activated T cells did not differ (Fig. 6). Also,
comparison of cytokine patterns following ex vivo stimulation of T
cells from the infected and the non-infected cohort revealed no
differences (data not shown).
Serum concentrations of steroids and metanephrine were
increased in patients that went on to develop infection, further
supporting a role of these hormones in the immunosuppression
Figure 4. Lack of CTLA-4 expression and inhibition by
catecholamines. A) The percentage of PBMC expressing CTLA-4 is
undistinguishable between healthy controls (white bars) and stroke
patients (grey bars) in the first two weeks following stroke. Medians and
interquartile ranges. n=9; 31; 33; 27; 20; (control; day 0; day 1; day 7;
day14). B) Percentage of CTLA-4 expression on PBMC decreases after in
vitro treatment with PHA + epinephrine or PHA + norepinephrine
compared to treatment with PHA alone. *** p,0.001. Medians and
interquartile ranges. .n=13; 6; 9; (PHA; PHA + Epi; PHA + Norepi).
doi:10.1371/journal.pone.0008718.g004
T Cell Function after Stroke
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8718following stroke (Fig. 7). In addition, serum IL-6 levels and IL-10
levels were significantly increased in the subgroup with subsequent
infection as reported previously [7] and confirmed within this
cohort (data not shown). However, this was not paralleled by
differences between the two patient groups for other proinflamma-
tory serum cytokine or HMGB1 concentrations (data not shown).
Discussion
Previous studies have addressed the changes in serum
cytokines and cellularity following ischemic stroke in humans
[5,6,7,17,18,19]. This study expands the recent findings and
addresses the activation status and the ex vivo functionality of
surviving T-lymphocytes from peripheral blood from post- stroke
patients, for only little information has been available on this aspect.
In comparison to healthy controls; stroke patients demonstrated
an enhanced surface expression of HLA-DR and CD25 on T cells,
revealing that stroke leads to T cell activation. Furthermore ex
vivo stimulation assays demonstrate normal proliferative responses
and enhanced secretion of proinflammatory cytokines, which
argues for Th1 priming in stroke patients. The apparent
contradiction of intact T cell responses and decreased proin-
flammatory serum cytokines can be reconciled when the
pronounced T cell loss in stroke is taken into account. This
Figure 5. Surviving T lymphocytes are functional. A) The proliferation expressed as stimulation index of T cells after ex vivo stimulation with
PHA reveals normal proliferative responses of stroke patients (grey bars) lymphocytes compared to healthy controls (white bars) in the first week
following stroke. Medians and interquartile ranges. n=7; 36; 35; 32; (control; day 0; day 1; day 7). B–E) Ex vivo stimulation of T cells with PHA leads to
increased proinflammatory cytokine release in supernatants of stroke patients cells (grey bars) compared to healthy controls (white bars) within the
first week following stroke. * p,0.05; ** p,0.01. Medians and interquartile ranges. n(IL-1b, IL-6, TNFa, TNF-b)=10; 37; 36; 28; (control; day 0; day 1; day 7).
doi:10.1371/journal.pone.0008718.g005
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reported lower TNF-a secretion when stimulating defined volumes
of whole blood ex vivo [20]. Also stroke has been shown to result
in decreased proinflammatory cytokine secretion by other cell
types such as macrophages resulting in the net-decrease of serum
cytokines despite enhanced T-cell activation [6].
Urraet al have reported that a reduced proportionof CD4+CD3+
T-cells contain TNF-a when stimulated for 4hrs with PMA-
Ionomycin [19]. This difference may be explained by the mitogens
used in the studies: PMA-Iononmycin but not PHA has been shown
to rapidly downregulate CD4 expression on T-cells [21]. Therefore
PMA-Ionomycin activated CD4+ T-cells producing TNF-a may be
missed when combined with FACS analysis gating on CD4+ T-cells.
CTLA-4, a tightly regulated T cell surface molecule, is upregulated
following activation of both, Treg and T effector cells [22]. CTLA-4
has an important inhibitory function in T cell regulation, and is
assumed to mediate immunosuppressive properties of human Foxp3
+
Treg cells [23]. In this study, CTLA-4 surface expression remained at
the level of healthy age-matched individuals even though other
surface markers of T-cell activation were upregulated.
Our in vitro data suggest that the catecholamine release
following stroke is causally related with the inhibition of CTLA-
4 induction in activated T cells. While the concentrations of
catecholamines used for these in vitro experiments exceed serum
levels they did not induce T-cell apoptosis. We conclude that the
catecholamine concentrations chosen for the in vitro experiments
are below the concentrations occurring in vivo where catechol-
amine induced apoptosis has been observed [4]. The catechol-
amine mediated inhibition of CTLA-4 expression in activated T
cells might reflect one of the key events leading to poststroke
activatability and Th1 priming of T cells.
While the pathophysiology of stroke induced lymphocyte loss is
increasingly understood, the mechanisms resulting in T cell
activation are largely unknown. HMGB1 is known to induce
proliferation and Th1 priming of T-lymphocytes and is released
into serum by activated epithelium and by tissue undergoing
necrosis. HMGB1 is therefore a candidate molecule that could
serve as possible mediator of T cell activation in stroke. Indeed, in
a small series of stroke patients serum HMGB1 was elevated as
demonstrated in western blots. The natural inhibitors of HMGB1
sRage and esRage were not determined, though [13]. Here we
confirm and extend this previous observation since we also detected
increased serum concentrations of HMGB1 by ELISA in a larger
cohort of stroke patients. Importantly, this was not paralleled by an
increase in sRage and esRage, which are known to inhibit HMGB1.
Of note, the HMGB1 serum kinetics resemble closely the kinetics
observed for the absolute numbers of CD4
+ T-cells expressing
HLA-DR in this study. In addition, HMGB1 correlated with IL-6
serum concentration, a cytokine that is readily induced by HMGB1.
Together, these observations support the hypothesis that HMGB1
serves as a link between brain tissue destruction and peripheral
activation and Th1 priming of T-lymphocytes.
Figure 6. Relative proportion of activated T cells were undistinguishable between patient subgroups. Activation markers on
lymphocytes from stroke patients without subsequent infection (white bars) remained undistinguishable from those of stroke patients with
subsequent infection (grey bars) within the relative proportion of lymphocytes in the first two weeks following stroke. * p,0.05; ** p,0.01. Medians
and interquartile ranges. . n(CD4
+
CD25
+
, CD25
+
%CD4
+
)= 5 ;7 ;7 ;7 ;7 ;6 ;6 ;3 ;n (CD4
+
HLA-DR
+
, HLA-DR
+
%CD4
+
)=14; 12; 16; 11; 12; 9; 8; 5 (no infection day 0;
subsequent infection day 0; no infection day 1; subsequent infection day 1; no infection day 7; subsequent infection day 7; no infection day 14;
subsequent infection day 14).
doi:10.1371/journal.pone.0008718.g006
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to increased infection rates in this patient population has been
described over the last six years in animal models and human stroke
patients. There is converging evidence suggesting that a hormone
storm of catecholamines and steroids immediately after cerebral
ischemia results in T cell apoptosis and reduced MHC expression on
monocytes [4,6,19]. The data reported here also confirm the linkage
of hormone concentrations with subsequent infection [5,6,24]. In
addition, we and others have described several immunological
markersincluding CD4
+T-cell counts, serum IL-6 levels, and TNF-a
release by macrophages that are associated with the occurrence of
infection in stroke patients [5,6,7,20]. While the occurrence of
pneumonia in stroke patients is commonly considered to be a strong
independent predictor of clinical outcome this finding has recently
been disputed [6,25,26]. These differences may be related to the
variability of definitions used to define infected and non-infected
patients. In this study we used the identical stringent definitions of
post stroke infection and non-infected patients reported previously; as
a consequence, all parameters obtained on admission and on day 1
were determined in the absence of clinical and paraclinical signs of
infection. This rigorous approach has previously identified CD4
+ T-
cell counts, and serum IL-6 concentrations as independent predictors
of infection [7].
In the current study, we demonstrate that the surviving T-cells
in the peripheral blood are activated and secrete proinflammatory
cytokines. These data could be interpreted as evidence supporting
the hypothesis that susceptibility to bacterial infections is a
quantitative effect of low CD4
+ T-cell counts. Alternatively, low
CD4
+ T-cell counts might represent a surrogate marker that is
closely related to the magnitude of multiple immunosuppressive
effects induced by cerebral ischemia. The challenge will now be to
identify the causative immune suppressive mechanisms.
In summary, here we provide a detailed analysis of T cell
functionality in stroke patients. We demonstrate a rapid activation
of T cells that are primed towards a Th1 response. This was true
for both patient subgroups; those with and those without
subsequent infection.
Our data point towards two mechanisms which may mediate
the activation of T cells in stroke patients: while increased
HMGB1serum levels may activate surviving lymphocytes in stroke
patients a downregulatory mechanism, the expression of CTLA-4
remains suppressed.
Further studies are needed to characterize the immunosuppres-
sive cascades triggered by cerebral ischemia. Investigators should
take into account that immune suppression may also have
beneficial effects by preventing secondary autoimmune disorders.
To which degree the stroke induced alterations of the immune
system that apparently maintain self tolerance but enhance
susceptibility to infection might rely on different mechanisms is
an open question of greatest clinical relevance.
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